INTRODUCTION
months were included in the study. Epidemiological data (demographic data), additional atopic (persistent rhinitis, seasonal rhinitis, urticaria, and dermatitis) and comorbid (diabetes mellitus, hypertension, gastroesophageal reflux, depression, and obesity) diseases, oral hygiene (dry mouth, dental caries, mouth rinse status), all lifelong history of fungal infections (oropharyngeal, nail, inguinal, foot, vaginal, skin, etc.), and medications used for infections and asthma were recorded using a questionnaire administered by a trained physician.
Concomitant use of 2 different ICS, or inhaled and oral corticosteroids together was defined as combined corticosteroid treatment. Atopy was defined as ≥ 1 positive skin prick tests. Skin prick testing to aeroallergens included pollens ( (range: 16-89 years) and mean age of onset of asthma was 36.1±15.57 years. In all, 147 (79%) of the patients had ≥1 additional atopic diseases. The lifelong incidence of oral candidiasis was 19.4% (n=36), whereas 5.38% (n=10) already had it at the time of the study. The lifelong incidence of any type of fungal infection was 59.7% (n=111), whereas 6.4% (n=12) already had one at the time of the study (Table 1) .
There weren't any significant differences in gender (p=0.264), age (p=0.752), age of onset of asthma (p=0.679), additional atopic diseases (p=0.106), diabetes mellitus (p=0.341), obesity (p=0.215), gastroesophageal reflux (p=0.575), dry mouth (p=0.913), dental caries (p=0.057), mouth rinse status (p=0.414), or atopy (p=0.934) between the OPC-positive and OPC-negative groups ( Table 2) . Among the 26 patients with a history of vaginal candidiasis following antibiotic use, only 7 had a history of OPC. There weren't any significant differences between a history of vaginal candidiasis after antibiotic usage and OPC. A history of persistent rhinitis (p=0.034), use of a leukotriene receptor antagonist together with an ICS, and use of ciclesonide as an ICS (p≤0.001) were associated with an higher frequency of (≥2) OPC infection (Table 3) .
DISCUSSION
In the present study the incidence of OPC in adult asthma patients was quite high (19.7), but no definitive risk factors were identified. According to the literature, the incidence of OPC (infection or colonization) in adult asthma patients ranges from <1% to 70%, depending on the diagnostic criteria used [8] . The variability in the incidence of OPC might also be the result of the fact that OPC does not always cause symptoms; only 33% of patients with OPC complain of sore throat or hoarseness. One review reported that OPC occurred in ≤ 5% of adult patients receiving ICS, of which ≥25% had positive mouth cultures [9] .
The incidence of OPC can vary with ICS formulation, dose, and dosing frequency [10, 11] . An increased risk of OPC has also been associated with concomitant use of oral corticosteroids, antibiotics, and diabetes medications [12] . In the present study the use of combined corticosteroid treatment was associated with an increase in the frequency of OPC, whereas comorbid diabetes mellitus was not. According to Turkish and international guidelines, a moderate dose of ICS in combination with a leukotriene receptor antagonist is recommended for patients with moderate-severe asthma [1, 13] . Use of a leukotriene receptor antagonist together with ICS was associated with an increased frequency of OPC in the present study, which might have due to the fact that most of the included patients had moderate-severe asthma and were receiving high-dose, long-term ICS treatment. Pinto et al. reported a cross-sectional study that included 200 moderate or severe asthma patients and observed no statistically significant difference between the groups of patients with and without self-reported adverse effects for any of charactersitcs (age, sex, dose of ICS, use of dry powder inhaler and metered dose inhaler, duration of ICS use, nasal corticosteroid use, oral hygiene after ICS use) and in terms of frequency of local symptoms between medium and high doses of ICS using patients [14] . Intrinsic inflammation of the upper airways in Turk Thorac J 2019; 20(2): 136-9 138 asthma patients, mechanical irritation caused by coughing, concomitant inflammatory diseases (e.g. rhinitis), and concomitant inflammatory environmental factors (e.g. air pollution) may also have an effect on the local side effects of ICS [7] . In the present study a history of persistent rhinitis was associated a history of OPC.
Many ICS (i.e. fluticasone propionate and budesonide) are inhaled in their pharmacologically active form, whereas other ICS (ciclesonide and beclomethasone dipropionate) are inhaled as inactive compounds and are activated by esterases in the lungs. Such on-site activation is important for reducing the potential local side effects of ICS by limiting the availability of active drug beyond the target tissue [13] .
Interestingly, in the present study frequent OPC infection was associated with use of ciclesonide as an ICS, which might have been the result of physicians prescribing ciclesonide to patients with a history of OPC.
The present study has some limitations, including its crosssectional design and the fact that the types and doses of ICS at the time of OPC were not recorded. In addition, medications were recorded as current treatment and the diagnosis of OPC and systemic candidiasis was made according to patient reports.
In conclusion, the frequency of OPC in the present study's adult asthma patients receiving regular ICS treatment was quite high. OPC has a negative effect on patient quality of life and treatment compliance. Despite the fact that no risk fac-tors for OPC were identified in the present study, we think that asthma patients should be informed about this side-effect at the beginning of ICS treatment. Further studies are needed to distinguish these individual differences. 
